From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Examining Ibrutinib as Secondline Therapy for Chronic Graft-Versus-Host Disease

On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
WIB_icon

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
WIB_icon

Do Patients With Lower-Risk MDS Benefit From Low-Dose Hypomethylating Agents?

The hypomethylating agents (HMAs) azacitidine and decitabine have been shown to improve survival and/or delay disease progression in patients with higher-risk myelodysplastic syndromes (MDS),...
WIB_icon

Patients With Sickle Cell Disease at Increased Risk for Hematologic Cancers, Especially Leukemia

As the treatment of patients with sickle cell disease (SCD) has improved, patients are now living to an age at which the risk of...
WIB_icon

Investigating a Venetoclax-Based Triplet Therapy for Patients With Relapsed/Refractory Myeloma

In a phase Ib trial of patients with relapsed/refractory multiple myeloma, targeting BCL2 and MCL1 with a triplet combination of the BCL2 inhibitor venetoclax...
WIB_icon

Number of Older Patients Receiving AlloHCT Increased Over the Past Decade

Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
WIB_icon

Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia

In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
WIB_icon

Examining Vorinostat to Prevent Graft-Versus-Host Disease After Unrelated Donor HCT

While the histone deacetylase (HDAC) inhibitor vorinostat led to a low incidence of acute graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT) with reduced-intensity...
WIB_icon

Ruxolitinib Versus Best Available Therapy for Essential Thrombocythemia

Treatment with the JAK1/2 inhibitor ruxolitinib failed to improve response rates, compared with best-available therapy (BAT) in patients with essential thrombocythemia (ET) who were...

Can Reduced-Dose Rituximab Effectively Prevent TTP Recurrence?

Previous research suggests that the anti-CD20 monoclonal antibody rituximab, at a dose of 375 mg/m2, can prevent relapse in patients with thrombotic thrombocytopenic purpura...
Advertisement

Current Issue

October 2017, Volume 3, Issue 12

This issue features a look at hospital ranking systems, the risks and benefits of opioids for pain management, and more.